SCHEMBL25815335

SCHEMBL25815335

COc1c[nH]c2nc(NC(c3ccccc3)(c3ccccc3)c3ccccc3)[nH]c(=O)c12

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 2/20 0.36
POLB P06746 2/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
TSHR P16473 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
KDM4E B2RXH2 1/20 0.34
ADORA2A P29274 2/20 0.34
RECQL P46063 1/20 0.34
PDGFRB P09619 1/20 0.34
MAOB P27338 1/20 0.33
TNKS O95271 1/20 0.33
TNKS2 Q9H2K2 1/20 0.33
PARP2 Q9UGN5 1/20 0.33
BRD4 O60885 1/20 0.33
FGFR1 P11362 1/20 0.33
FGFR2 P21802 1/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25390339 0.81 MAPT (0.33) MEN1KMT2ASMN1; SMN2KDM4EMAPT
SCHEMBL17652009 0.80 KMT2A (0.35) MEN1KMT2AKDM4E
SCHEMBL17652022 0.78 CHUK (0.43) KDM4E
SCHEMBL25388131 0.76 HPGD (0.35) POLBMEN1KMT2ATSHRSMN1; SMN2
SCHEMBL19253836 0.74 TYMS (0.34) KDM4E
SCHEMBL17652032 0.74 TYMS (0.34) MEN1KMT2ATSHRSMN1; SMN2KDM4E
SCHEMBL17652035 0.74 LMNA (0.35) POLBMEN1KMT2ASMN1; SMN2KDM4E
SCHEMBL25389586 0.73 MEN1 (0.38) MEN1KMT2ARECQL
SCHEMBL5198845 0.72 KDM4E (0.41) MEN1KMT2ASMN1; SMN2KDM4ETNKS
SCHEMBL5196594 0.72 KDM4E (0.41) MEN1KMT2ASMN1; SMN2KDM4ETNKS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11684611-B2 Compounds for treating diseases associated with a mitochondrial dysfunction AMABIOTICS (FR) 2023-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11684611-B2 Compounds for treating diseases associated with a mitochondrial dysfunction NDUFAB1, FH, TFAM KCNA5 1639/4885POLB 788/4885MEN1 3146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.